Innovation comes in many shapes and sizes

In an industry littered with discontinued programs and dashed hopes, Merck is placing some contrarian bets on therapeutic approaches that others have abandoned.

While competitors retreat from challenging modalities or write off entire target classes after early setbacks, Merck’s strategy centres on a simple premise: the first attempt rarely gets it right.

By focusing on next generation agents with improved therapeutic windows and enhanced combinability, they’re revisiting the graveyard of oncology development with fresh eyes and deeper pockets.

The question isn’t whether their pipeline agents will work in isolation, but whether they can succeed where previous iterations failed spectacularly and leverage the science to generate approaches, which could make their competitors irrelevant…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers